NCT04588038 - NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions

Recurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaResectable Oropharyngeal Squamous Cell Carcinoma

Interventions

BIOLOGICAL

Efineptakin alfa

Given via intramuscular injection

Trial Locations (1)

94143

University of California San Francisco, San Francisco